Skip to content

Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device

Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02718963
Enrollment
20
Registered
2016-03-24
Start date
2015-07-15
Completion date
2016-06-24
Last updated
2020-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deglutition Disorders

Brief summary

The purpose of this study is to determine the synchronized electrical stimulation device effective in the treatment of dysphagia.

Detailed description

* Design: Prospective study * Inclusion criteria of the patient group: who has a dysphagia symptom and confirmed by video-fluoroscopic swallowing study(N=10) * Inclusion criteria of the control group: who does not have any dysphagia symptoms, and does not have any underlying disease(N=10) * Setting: Hospital rehabilitation department * Intervention: Participants are applied electrical stimulation by a Synchronized Electrical Stimulation Device(SESD)

Interventions

DEVICESynchronized Electrical Stimulation Device

electrical stimulation at muscles which related with deglutition

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* who have dysphagia symptoms and verified deglutition disorder by video fluoro swallowing study

Exclusion criteria

* who reject the checkup their deglutition function by high resolution manometry * who reject apply Synchronized Electrical Stimulator

Design outcomes

Primary

MeasureTime frameDescription
Pressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.During the electrical stimulation and electrical stimulation effects of Velopharynx, tongue base, lower pharynx and upper esophageal sphincterMaximal pressure, integral, rise time, and duration in the regions of VP and TB (the time interval over the VP and TB integral). The maximal pressure of low pharynx (LP) (C in supplementary 1), maximal pre-upper esophageal sphincter (UES) pressure (F in supplementary 1), maximal cricopharyngeus (CP) pressure (D in supplementary 1), minimal upper esophageal sphincter (UES) pressure, upper esophageal sphincter (UES) activity time (the interval between pre-upper esophageal sphincter (UES) peak and post-upper esophageal sphincter (UES) peak; G in supplementary 1), and nadir upper esophageal sphincter (UES) pressure duration in the region of upper esophageal sphincter (UES).

Countries

South Korea

Participant flow

Pre-assignment details

There was no significant event in the study after participant enrollment

Participants by arm

ArmCount
Control Group
* control group(N=10): who does not have dysphagia symptom * apply Synchronized Electrical Stimulation Device * before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function * during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function Synchronized Electrical Stimulation Device: electrical stimulation at muscles which related with deglutition
10
Experimental Group
* experimental group(N=10): who have dysphagia symptoms * apply Synchronized Electrical Stimulation Device * before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function * during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function Synchronized Electrical Stimulation Device: electrical stimulation at muscles which related with deglutition
10
Total20

Baseline characteristics

CharacteristicControl GroupExperimental GroupTotal
Age, Continuous51.6 years
STANDARD_DEVIATION 11.99
65.9 years
STANDARD_DEVIATION 13.06
58.75 years
STANDARD_DEVIATION 12.5
Disease
Brain tumor
0 Participants1 Participants1 Participants
Disease
Cerebral palsy
0 Participants1 Participants1 Participants
Disease
Guillain-Barre syndrome
0 Participants1 Participants1 Participants
Disease
Healthy
10 Participants0 Participants10 Participants
Disease
Spinal cord injury
0 Participants1 Participants1 Participants
Disease
Stroke
0 Participants4 Participants4 Participants
Disease
Unknown
0 Participants2 Participants2 Participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
South Korea
10 participants10 participants20 participants
Sex: Female, Male
Female
4 Participants2 Participants6 Participants
Sex: Female, Male
Male
6 Participants8 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 10
other
Total, other adverse events
0 / 100 / 10
serious
Total, serious adverse events
0 / 100 / 10

Outcome results

Primary

Pressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.

Maximal pressure, integral, rise time, and duration in the regions of VP and TB (the time interval over the VP and TB integral). The maximal pressure of low pharynx (LP) (C in supplementary 1), maximal pre-upper esophageal sphincter (UES) pressure (F in supplementary 1), maximal cricopharyngeus (CP) pressure (D in supplementary 1), minimal upper esophageal sphincter (UES) pressure, upper esophageal sphincter (UES) activity time (the interval between pre-upper esophageal sphincter (UES) peak and post-upper esophageal sphincter (UES) peak; G in supplementary 1), and nadir upper esophageal sphincter (UES) pressure duration in the region of upper esophageal sphincter (UES).

Time frame: During the electrical stimulation and electrical stimulation effects of Velopharynx, tongue base, lower pharynx and upper esophageal sphincter

ArmMeasureGroupValue (MEAN)Dispersion
Control GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.Control, pressure of VP, thin162.04 mmHgStandard Deviation 39.67
Control GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.NMES, pressure of VP, thin200.90 mmHgStandard Deviation 70.61
Control GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.Control, pressure of tongue base, thick81.59 mmHgStandard Deviation 44.51
Control GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.NMES, pressure of tongue base, thick109.22 mmHgStandard Deviation 54.36
Experimental GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.NMES, pressure of tongue base, thick151.26 mmHgStandard Deviation 34.86
Experimental GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.Control, pressure of VP, thin129.66 mmHgStandard Deviation 45.58
Experimental GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.Control, pressure of tongue base, thick136.40 mmHgStandard Deviation 27.2
Experimental GroupPressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter.NMES, pressure of VP, thin170.66 mmHgStandard Deviation 77.1
Comparison: Wilcoxon signed rank test was used to compare the Videofluoroscopic swallowing study(VFSS) kinematic variables, VDS, PAS, and high resolution manometry (HRM) variables between the neuromuscular electrical stimulation session and the control session in swallowing thin fluid and thick fluid for healthy, dysphagic and whole participants. Mann-Whitney test was used to compare the differences of VFSS variables, VDS, PAS, and HRM variables between the healthy participants and dysphagic participants.p-value: <0.05Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026